We are international
Donate
• IMF TV TEXT SIZE   
webcasts from medical meetings    back

Paul Richardson, MD, Dana Farber Cancer Institute, Boston, MA
06.06.04

Be the first to comment

 related articles
Understanding VELCADE as a Subcutaneous (SQ) Injection
New! Tip Card on Subcutaneous VELCADE
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Patients Personifying Progress: Mary Ming-Mosely
Subcutaneous VELCADE® Site
The VELCADE® Website
VELCADE® Downloadable Resources
Randomized Phase III Study Comparing Conventional-Dose Treatment Using a Combination of Lenalidomide (Revlimid®), Bortezomib (Velcade®), and Dexamethasone (RVD) to High-Dose Treatment with Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Open Velcade® (bortezomib) Trials
Eastern Cooperative Oncology Group Clinical Trial:E1A05
Understanding VELCADE® (bortezomib) for Injection
Subcutaneous VELCADE® Approved in the EU for the Treatment of Multiple Myeloma
VELCADE® Webcasts from the 2012 American Society of Clinical Oncology (ASCO) Meeting
VELCADE® Webcasts from the 2011 American Society of Hematology (ASH) Annual Meeting
Millennium's VELCADE Reimbursement Assistance Program
Millennium: The Takeda Oncology Company's Web Site
Archived VELCADE Webcasts
News About VELCADE®


You might also be interested in:

General Information
Understanding VELCADE as a Subcutaneous (SQ) Injection
Two short videos explaining what you need to know about VELCADE SQ.

New! Tip Card on Subcutaneous VELCADE

FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Study met primary efficacy endpoint of non-inferiority between subcutaneous and intravenous administration.
Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy.

Patients Personifying Progress: Mary Ming-Mosely
Two months ago, I started on VELCADE subcutaneous. It’s just a shot. I don’t have to wait for an IV. It’s just in-and-out. VELCADE has kept me going and feeling well enough to live my life.

Subcutaneous VELCADE® Site
The US Food and Drug Administration (FDA) has approved subcutaneous VELCADE for the treatment of multiple myeloma. This approval was based on a large, international clinical trial that studied VELCADE injected under the skin compared with VELCADE injected into a vein. The 222 patients in this study had been treated for their myeloma and relapsed.

The VELCADE® Website
Information for patients and clinicans on indications and usage.

VELCADE® Downloadable Resources

Clinical Trials
Randomized Phase III Study Comparing Conventional-Dose Treatment Using a Combination of Lenalidomide (Revlimid®), Bortezomib (Velcade®), and Dexamethasone (RVD) to High-Dose Treatment with Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

This study, sponsored by Dr. Paul Richardson of the Dana-Farber Cancer Institute, was designed to answer a very important question in myeloma: In the era of novel drugs, is high-dose therapy (HDT) still necessary in the initial management of multiple myeloma in younger patients? In this study, the addition of HDT to conventional dose treatment (RVD) as compared to conventional-dose treatment (RVD) alone would be considered superior if it significantly prolongs progression-free survival by at least 9 months.


Open Velcade® (bortezomib) Trials

Eastern Cooperative Oncology Group Clinical Trial:E1A05
Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) & Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®:) - Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen

Publications
Understanding VELCADE® (bortezomib) for Injection
Part of the IMF's Understanding series, this booklet covers the basics, including: What is VELCADE®? How does it work? How is VELCADE® given? How is it used in clinical practice today? What are the side effects?

News
Subcutaneous VELCADE® Approved in the EU for the Treatment of Multiple Myeloma
The approval is based on data from a Phase III study demonstrating that subcutaneous administration of bortezomib is equally effective as intravenous bortezomib but is associated with a significant reduction in the frequency and severity of side effects.

Webcasts About Velcade
VELCADE® Webcasts from the 2012 American Society of Clinical Oncology (ASCO) Meeting

VELCADE® Webcasts from the 2011 American Society of Hematology (ASH) Annual Meeting
The experts talk about VELCADE® in clinical trials, as frontline therapy and for relapsed patients, alone and in trials with various other agents in nine webcasts.

Links
Millennium's VELCADE Reimbursement Assistance Program
Program is available to patients, physicians, and caregivers to provide assistance regarding reimbursement issues related to the use of VELCADE® (bortezomib) for Injection.

Millennium: The Takeda Oncology Company's Web Site

Archive
Archived VELCADE Webcasts
Webcasts on VELCADE research from past medical meetings.

News About VELCADE®
Past articles and press releases about VELCADE.